Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone

Khalid Mohammad, Carol G. Chen, Guive Balooch, Elizabeth Stebbins, C. Ryan McKenna, Holly Davis, Maria Niewolna, Xiang Hong Peng, Daniel H N Nguyen, Sophi S. Ionova-Martin, John W. Bracey, William R. Hogue, Darren H. Wong, Robert O. Ritchie, Larry J. Suva, Rik Derynck, Theresa Guise, Tamara Alliston

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF-β has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF-β signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-β signaling on bone remain unclear. To examine the role of TGF-β in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF-β type I receptor (TβRI) kinase on bone mass, architecture and material properties. Inhibition of TβRI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro-mechanical behavior of vertebral bone. TβRI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TβRI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, TβRI inhibitors may be effective in treating conditions of skeletal fragility.

Original languageEnglish (US)
Article numbere5275
JournalPLoS One
Volume4
Issue number4
DOIs
StatePublished - Apr 16 2009
Externally publishedYes

Fingerprint

Bone
phosphotransferases (kinases)
Phosphotransferases
bones
Bone and Bones
receptors
Osteoclasts
Osteoblasts
osteoclasts
osteoblasts
Materials properties
Bone Matrix
Bone Development
Bone Fractures
Bone Resorption
bone fractures
skeletal development
bone resorption
Osteogenesis
Skeleton

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. / Mohammad, Khalid; Chen, Carol G.; Balooch, Guive; Stebbins, Elizabeth; McKenna, C. Ryan; Davis, Holly; Niewolna, Maria; Peng, Xiang Hong; Nguyen, Daniel H N; Ionova-Martin, Sophi S.; Bracey, John W.; Hogue, William R.; Wong, Darren H.; Ritchie, Robert O.; Suva, Larry J.; Derynck, Rik; Guise, Theresa; Alliston, Tamara.

In: PLoS One, Vol. 4, No. 4, e5275, 16.04.2009.

Research output: Contribution to journalArticle

Mohammad, K, Chen, CG, Balooch, G, Stebbins, E, McKenna, CR, Davis, H, Niewolna, M, Peng, XH, Nguyen, DHN, Ionova-Martin, SS, Bracey, JW, Hogue, WR, Wong, DH, Ritchie, RO, Suva, LJ, Derynck, R, Guise, T & Alliston, T 2009, 'Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone', PLoS One, vol. 4, no. 4, e5275. https://doi.org/10.1371/journal.pone.0005275
Mohammad, Khalid ; Chen, Carol G. ; Balooch, Guive ; Stebbins, Elizabeth ; McKenna, C. Ryan ; Davis, Holly ; Niewolna, Maria ; Peng, Xiang Hong ; Nguyen, Daniel H N ; Ionova-Martin, Sophi S. ; Bracey, John W. ; Hogue, William R. ; Wong, Darren H. ; Ritchie, Robert O. ; Suva, Larry J. ; Derynck, Rik ; Guise, Theresa ; Alliston, Tamara. / Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. In: PLoS One. 2009 ; Vol. 4, No. 4.
@article{258582e4ee574148a06569561fe98574,
title = "Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone",
abstract = "During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF-β has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF-β signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-β signaling on bone remain unclear. To examine the role of TGF-β in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF-β type I receptor (TβRI) kinase on bone mass, architecture and material properties. Inhibition of TβRI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro-mechanical behavior of vertebral bone. TβRI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TβRI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, TβRI inhibitors may be effective in treating conditions of skeletal fragility.",
author = "Khalid Mohammad and Chen, {Carol G.} and Guive Balooch and Elizabeth Stebbins and McKenna, {C. Ryan} and Holly Davis and Maria Niewolna and Peng, {Xiang Hong} and Nguyen, {Daniel H N} and Ionova-Martin, {Sophi S.} and Bracey, {John W.} and Hogue, {William R.} and Wong, {Darren H.} and Ritchie, {Robert O.} and Suva, {Larry J.} and Rik Derynck and Theresa Guise and Tamara Alliston",
year = "2009",
month = "4",
day = "16",
doi = "10.1371/journal.pone.0005275",
language = "English (US)",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone

AU - Mohammad, Khalid

AU - Chen, Carol G.

AU - Balooch, Guive

AU - Stebbins, Elizabeth

AU - McKenna, C. Ryan

AU - Davis, Holly

AU - Niewolna, Maria

AU - Peng, Xiang Hong

AU - Nguyen, Daniel H N

AU - Ionova-Martin, Sophi S.

AU - Bracey, John W.

AU - Hogue, William R.

AU - Wong, Darren H.

AU - Ritchie, Robert O.

AU - Suva, Larry J.

AU - Derynck, Rik

AU - Guise, Theresa

AU - Alliston, Tamara

PY - 2009/4/16

Y1 - 2009/4/16

N2 - During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF-β has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF-β signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-β signaling on bone remain unclear. To examine the role of TGF-β in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF-β type I receptor (TβRI) kinase on bone mass, architecture and material properties. Inhibition of TβRI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro-mechanical behavior of vertebral bone. TβRI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TβRI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, TβRI inhibitors may be effective in treating conditions of skeletal fragility.

AB - During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF-β has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF-β signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-β signaling on bone remain unclear. To examine the role of TGF-β in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF-β type I receptor (TβRI) kinase on bone mass, architecture and material properties. Inhibition of TβRI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro-mechanical behavior of vertebral bone. TβRI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TβRI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, TβRI inhibitors may be effective in treating conditions of skeletal fragility.

UR - http://www.scopus.com/inward/record.url?scp=65349134769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349134769&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0005275

DO - 10.1371/journal.pone.0005275

M3 - Article

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e5275

ER -